RT Journal Article
SR Electronic
T1 Atypical antipsychotics: New drugs, new challenges
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 597
OP 606
VO 74
IS 8
A1 Mathews, Manu
A1 Muzina, David J.
YR 2007
UL http://www.ccjm.org/content/74/8/597.abstract
AB Compared with the first-generation, or “typical” antipsychotic drugs, second-generation or atypical antipsychotics cause fewer extrapyramidal (motor) problems, but they pose new challenges, as they often contribute to metabolic disturbances such as weight gain, hyperlipidemia, insulin resistance, and type 2 diabetes mellitus. Patients taking atypical antipsychotics should be monitored for glycemic and cardiovascular risk factors and should receive treatment for such problems as they arise.